Filing search / Fusion Pharmaceuticals Inc / "Nature"

DEFM14A

FUSN Fusion Pharmaceuticals Inc

25 Apr 24

Proxy related to merger

4:13pm

that would be most likely to have interest in Fusion, be able to move decisively and have the ability to consummate a transaction of this size and nature … information presented in this section is forward-looking in nature and, therefore, the information should be read in light of the factors discussed

PREM14A

FUSN Fusion Pharmaceuticals Inc

10 Apr 24

Preliminary proxy related to merger

4:42pm

of this size and nature, and therefore, directed Centerview to continue discussions with Party B, Party C and Party D and to also contact an additional … Committee) and certain information presented in this section is forward-looking in nature and, therefore, the information should be read in light

DEFA14A

q5t9qcat

19 Mar 24

Additional proxy soliciting materials

6:25am

8-K

EX-2.1

deq5u 5bmp50dfzuth

19 Mar 24

Voting and Support Agreement

6:24am

8-K

EX-99.1

thjt7tdycxvf0b

19 Mar 24

Voting and Support Agreement

6:24am

8-K

EX-10.1

y37vncrl6uafa08imfj

16 Feb 24

Entry into a Material Definitive Agreement

4:05pm

424B5

qv5w0rt1566j

19 Jan 24

Prospectus supplement for primary offering

4:10pm

8-K

EX-10.1

jzegdn

11 May 23

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates

7:46am